Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention: From the FU-Registry

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 791-799

  Ike, Amane ^a   Nishikawa, Hiroaki ^a   Shirai, Kazuyuki ^a   Mori, Ken ^a   Kuwano, Takashi ^a   Fukuda, Yusuke ^a   Takamiya, Yosuke ^a   Yanagi, Daizaburo ^a   Kubota, Kazumitsu ^a   Tsuchiya, Yoshihiro ^a   Zhang, Bo ^a   Miura, Shin ichiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical outcome; Diabetes mellitus; Glycemic control; Percutaneous coronary intervention

Indexed keywords

HEMOGLOBIN A1C;

ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; BLOOD GLUCOSE; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED;

EID: 79953652407     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0474     Document Type: Article

References (30)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
2. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: Sixteen year follow-up study. Diabetes 1974; 23: 105-111.
3. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005; 293: 1501-1508.
4. Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, et al. Beyond restenosis: Five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004; 110: 1226-1230.
5. Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP Jr, et al. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol 2006; 98: 718-721.
6. Nakatani D, Sakata Y, Mizuno H, Shimizu M, Suna S, Usami M, et al; Osaka Acute Coronary Insufficiency Study (OACIS) Group. Impact of diabetes mellitus on rehospitalization for heart failure among survivors of acute myocardial infarction in the percutaneous coronary intervention era. Circ J 2009; 73: 662-666.
7. Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
8. Farah R, Shurtz-Swirski R, Lapin O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. Cardiovasc Diabetol 2008; 7: 20.
9. Tchaikovski V, Olieslagers S, Bohmer FD, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 2009; 120: 150-159.
10. McBane RD 2nd, Hardison RM, Sobel BE; BARI 2D Study Group. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). Am J Cardiol 2010; 105: 17-24.
11. Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, et al. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J Cardiol 2006; 97: 1182-1187.
12. Corpus RA, George PB, House JA, Dixon SR, Ajluni SC, Devlin WH, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8-14.
13. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563-2569.
14. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290: 2159-2167.
15. Japan Diabetes Society Report. http://www.jds.or.jp/jds_or_jp0/uploads/photos/636.pdfl (accessed 10 August, 2010).
16. Guidelines for the primary prevention of ischemic heart disease revised version (JCS 2006). http://www.j-circ.or.jp/guideline/pdf/ JCS2006_kitabatake_h.pdf (accessed 10 August, 2010).
17. Fukuda Y, Shirai K, Miura S, Ike A, Takamiya Y, Kuwano T, et al. The impact of angulated lesions on angiographic late loss in patients with drug-eluting stent implantation. J Cardiol 2009; 53: 396-401.
18. Yanagi D, Shirai K, Takamiya Y, Fukuda Y, Kuwano T, Ike A, et al. Results of provisional stenting with a Sirolimus-eluting stent for bifurcation lesion: Multicenter study in Japan. J Cardiol 2008; 51: 89-94.
19. Iwata A, Miura S, Shirai K, Kawamura A, Tomita S, Matsuo Y, et al. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med 2006; 45: 885-890.
20. Mukai N, Doi Y, Ninomiya T, Hata J, Yonemoto K, Iwase M, et al. Impact of metabolic syndrome compared with impaired fasting glucose on the development of type 2 diabetes in a general Japanese population: The Hisayama study. Diabetes Care 2009; 32: 2288-2293.
21. Osawa H, Doi Y, Makino H, Ninomiya T, Yonemoto K, Kawamura R, et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: The Hisayama Study. Cardiovasc Diabetol 2009; 8: 60.
22. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44: 2293-2300.
23. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: A pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol 2008; 52: 255-262.
24. Garg P, Normand SL, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: Results from the Massachusetts Data Analysis Center Registry. Circulation 2008; 118: 2277-2285, 7p following 85.
25. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126.
26. Yamagata K, Kataoka Y, Kokubu N, Kasahara Y, Abe M, Nakajima H, et al. A 3-year clinical outcome after percutaneous coronary intervention using sirolimus-eluting stent and off-pump coronary artery bypass grafting for the treatment of diabetic patients with multivessel disease. Circ J 2010; 74: 671-678.
27. Kim KS. PCI vs CABG in complicated diabetic patients: Do we need more data to change the practical guideline? Circ J 2010; 74: 622-623.
28. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, et al. AHA consensus panel statement: Preventing heart attack and death in patients with coronary disease: The Secondary Prevention Panel. J Am Coll Cardiol 1995; 26: 292-294.
29. Maron DJ, Boden WE, O'Rourke RA, Hartigan PM, Calfas KJ, Mancini GB, et al; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: Optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010; 55: 1348-1358.
30. Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, et al. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: The ROSARY Study. J Lipid Res 2009; 50: 1832-1841.